SG11202108570SA - Anti-trem1 antibodies and related methods - Google Patents
Anti-trem1 antibodies and related methodsInfo
- Publication number
- SG11202108570SA SG11202108570SA SG11202108570SA SG11202108570SA SG11202108570SA SG 11202108570S A SG11202108570S A SG 11202108570SA SG 11202108570S A SG11202108570S A SG 11202108570SA SG 11202108570S A SG11202108570S A SG 11202108570SA SG 11202108570S A SG11202108570S A SG 11202108570SA
- Authority
- SG
- Singapore
- Prior art keywords
- related methods
- trem1 antibodies
- trem1
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802161P | 2019-02-06 | 2019-02-06 | |
| US201962889994P | 2019-08-21 | 2019-08-21 | |
| PCT/US2020/016949 WO2020163564A2 (en) | 2019-02-06 | 2020-02-06 | Anti-trem1 antibodies and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108570SA true SG11202108570SA (en) | 2021-09-29 |
Family
ID=71947128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108570SA SG11202108570SA (en) | 2019-02-06 | 2020-02-06 | Anti-trem1 antibodies and related methods |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3921344A4 (pt) |
| JP (1) | JP7492522B2 (pt) |
| KR (1) | KR20210126638A (pt) |
| CN (1) | CN113748132A (pt) |
| AU (1) | AU2020218525A1 (pt) |
| BR (1) | BR112021015479A2 (pt) |
| CA (1) | CA3128053A1 (pt) |
| CL (1) | CL2021002075A1 (pt) |
| CO (1) | CO2021010887A2 (pt) |
| CR (1) | CR20210462A (pt) |
| DO (1) | DOP2021000165A (pt) |
| IL (1) | IL284818A (pt) |
| MX (1) | MX2021009500A (pt) |
| PE (1) | PE20212269A1 (pt) |
| SG (1) | SG11202108570SA (pt) |
| TW (1) | TW202037613A (pt) |
| WO (1) | WO2020163564A2 (pt) |
| ZA (1) | ZA202210284B (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014086365A1 (en) * | 2012-12-03 | 2014-06-12 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| PT3653221T (pt) * | 2015-02-19 | 2022-11-08 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
| WO2017127933A1 (en) * | 2016-01-29 | 2017-08-03 | The Governing Council Of The University Of Toronto | Frizzled protein-binding agents and methods of use thereof |
| JP7023853B2 (ja) * | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| MX2018012469A (es) * | 2016-04-15 | 2019-07-04 | Immunext Inc | Anticuerpos vista antihumanos y uso de los mismos. |
-
2020
- 2020-02-06 BR BR112021015479A patent/BR112021015479A2/pt unknown
- 2020-02-06 AU AU2020218525A patent/AU2020218525A1/en active Pending
- 2020-02-06 WO PCT/US2020/016949 patent/WO2020163564A2/en unknown
- 2020-02-06 TW TW109103757A patent/TW202037613A/zh unknown
- 2020-02-06 PE PE2021001282A patent/PE20212269A1/es unknown
- 2020-02-06 MX MX2021009500A patent/MX2021009500A/es unknown
- 2020-02-06 CN CN202080027026.9A patent/CN113748132A/zh active Pending
- 2020-02-06 CR CR20210462A patent/CR20210462A/es unknown
- 2020-02-06 SG SG11202108570SA patent/SG11202108570SA/en unknown
- 2020-02-06 KR KR1020217028210A patent/KR20210126638A/ko unknown
- 2020-02-06 JP JP2021545857A patent/JP7492522B2/ja active Active
- 2020-02-06 CA CA3128053A patent/CA3128053A1/en active Pending
- 2020-02-06 EP EP20752176.6A patent/EP3921344A4/en active Pending
-
2021
- 2021-07-13 IL IL284818A patent/IL284818A/en unknown
- 2021-08-05 CL CL2021002075A patent/CL2021002075A1/es unknown
- 2021-08-06 DO DO2021000165A patent/DOP2021000165A/es unknown
- 2021-08-18 CO CONC2021/0010887A patent/CO2021010887A2/es unknown
-
2022
- 2022-09-16 ZA ZA2022/10284A patent/ZA202210284B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7492522B2 (ja) | 2024-05-29 |
| IL284818A (en) | 2021-08-31 |
| CR20210462A (es) | 2021-12-13 |
| WO2020163564A2 (en) | 2020-08-13 |
| DOP2021000165A (es) | 2021-09-30 |
| JP2022523145A (ja) | 2022-04-21 |
| BR112021015479A2 (pt) | 2021-12-28 |
| EP3921344A4 (en) | 2022-10-12 |
| CA3128053A1 (en) | 2020-08-13 |
| WO2020163564A3 (en) | 2020-09-24 |
| TW202037613A (zh) | 2020-10-16 |
| KR20210126638A (ko) | 2021-10-20 |
| PE20212269A1 (es) | 2021-11-30 |
| MX2021009500A (es) | 2021-09-08 |
| ZA202210284B (en) | 2023-03-29 |
| EP3921344A2 (en) | 2021-12-15 |
| CL2021002075A1 (es) | 2022-04-01 |
| AU2020218525A1 (en) | 2021-09-23 |
| CO2021010887A2 (es) | 2021-09-09 |
| CN113748132A (zh) | 2021-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272218A (en) | ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS | |
| ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281297A (en) | Anti-NPR1 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL287690A (en) | Antibodies against hvem and their use | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL289656A (en) | Anti-tigit antibodies and their application | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL283926A (en) | Antibodies against alpha-synuclein and their uses | |
| IL291546A (en) | Antibodies against kir3dl3 and their uses | |
| IL291550A (en) | Anti-il-27 antibodies and their uses | |
| IL291280A (en) | Antibodies against cd371 and their uses | |
| IL283890A (en) | Anti-periostin antibodies and their uses | |
| IL288807A (en) | Anti-talen antibodies and their uses |